Page 2 - வழி நடத்து ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from வழி நடத்து ப்ரோக்ர்யாம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In வழி நடத்து ப்ரோக்ர்யாம் Today - Breaking & Trending Today

Sunflowers and Hemp Could Reduce Lead in Burlington Soil


A monarch butterfly on a sunflower
When Laura Hill bought a house in Burlington s Old North End, she was warned about the lead. Until it was banned in the U.S. in 1978, lead paint was used in many homes. Lead remediation had been done inside the home, but Hill said there were likely still high levels of lead on and around the outside walls and in the soil.
It struck me, because it was my neighborhood and I saw people growing food in their yards next to their house, she said.
Hill is a plant biologist and senior lecturer at the University of Vermont. I m always looking for ways to improve life with plants, she said. ....

United States , Margaret Williams , Laura Hill , Mariah Cronin , Burlington Lead Program , Us Environmental Protection Agency , Burlington Community Economic Development Office , Environmental Program , Chernobyl Nuclear Power Plant , Environmental Testing Lab , University Of Vermont , Old North End , Protection Agency , Chittenden Solid Waste District , Environmental Depot , Community Economic Development Office , Lead Program , Environmental Testing , ஒன்றுபட்டது மாநிலங்களில் , மார்கரெட் வில்லியம்ஸ் , லாரா மலை , மரியா குரோனின் , பர்லிங்டன் வழி நடத்து ப்ரோக்ர்யாம் , பர்லிங்டன் சமூக பொருளாதார வளர்ச்சி அலுவலகம் , சுற்றுச்சூழல் ப்ரோக்ர்யாம் , சுற்றுச்சூழல் சோதனை ஆய்வகம் ,

Avidity Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Highlights


Share this article
Share this article
LA JOLLA, Calif., March 15, 2021 /PRNewswire/ Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2020 and highlighted recent corporate progress.       
In 2020, we made significant advances across our AOC pipeline and platform. Our work supports Avidity s evolution to a clinical-stage company as we plan to advance AOC 1001 into the clinic in the second half of this year and progress our FSHD and DMD programs, said Sarah Boyce, President and Chief Executive Officer.  Our discovery efforts continue to focus on expanding our AOC platform into additional muscle diseases and other tissues as we begin to realize our vision of profoundly improving people s lives by revolutionizing the delivery of RNA treatments. ....

United States , Tamar Thompson , Jean Kim , Amy Conrad , Mike Maclean , Eli Lilly , Bristol Meyers Squibb , Sarah Boyce , Myotonic Dystrophy Clinical Research Network , Prnewswire Avidity Biosciences Inc , Exchange Commission , Development Rd Expenses , Avidity Biosciences Inc , Diverse Team Members To Management , Antibody Oligonucleotide Conjugates , Chief Executive , Chief Financial , Lead Program , Broad Pipeline , Untreated Rare Muscle , Preclinical Proof Of Concept , Skeletal Muscle , Advancing Beyond Muscle , Discovery Efforts , Diverse Team Members , Cash Equivalents ,